ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,204,102 | -12.3% | 744,440 | -0.7% | 0.01% | -12.5% |
Q2 2023 | $23,047,100 | +27.4% | 749,743 | +49.4% | 0.01% | +14.3% |
Q1 2023 | $18,085,438 | -37.8% | 501,955 | -31.7% | 0.01% | -36.4% |
Q4 2022 | $29,054,513 | +47.0% | 735,185 | +49.5% | 0.01% | +22.2% |
Q3 2022 | $19,764,000 | +137.7% | 491,861 | +148.7% | 0.01% | +200.0% |
Q2 2022 | $8,316,000 | -55.3% | 197,799 | -58.6% | 0.00% | -50.0% |
Q1 2022 | $18,610,000 | +3.5% | 477,689 | +5.9% | 0.01% | +20.0% |
Q4 2021 | $17,977,000 | +70.9% | 451,110 | +54.9% | 0.01% | +66.7% |
Q3 2021 | $10,522,000 | -68.7% | 291,140 | -64.5% | 0.00% | -72.7% |
Q2 2021 | $33,594,000 | +73.3% | 819,544 | +84.4% | 0.01% | +83.3% |
Q1 2021 | $19,390,000 | +73.7% | 444,533 | +99.3% | 0.01% | +50.0% |
Q4 2020 | $11,165,000 | +395.6% | 223,086 | +316.6% | 0.00% | +300.0% |
Q3 2020 | $2,253,000 | +421.5% | 53,550 | +501.6% | 0.00% | – |
Q2 2020 | $432,000 | – | 8,901 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |